Fitzgerald Nicole D, Black Joshua C, Cottler Linda B, Martins Silvia S, Palamar Joseph J
Department of Epidemiology, Columbia Mailman School of Public Health, New York, New York.
Division of Denver Health, Rocky Mountain Poison & Drug Safety (RMPDS), Denver, Colorado.
Am J Prev Med. 2025 Jun 9;69(3):107742. doi: 10.1016/j.amepre.2025.107742.
Fentanyl-related deaths involving stimulants have increased in the U.S., but little is known about nonfatal overdoses involving use. This study examined national trends in nonfatal fentanyl-related exposures involving co-use of cocaine or methamphetamine.
In this cross-sectional analysis, data from U.S. poison centers were used to estimate annual trends in reported exposures involving fentanyl and stimulant use from 2015 to 2023. Cases included patients aged ≥13 with exposures involving intentional misuse or "abuse" of fentanyl where nonfatal adverse effects occurred (n=13,173). Co-exposure trends were examined, and multivariable logistic regression models were used to estimate how region and medical outcome severity were associated with (1) fentanyl-cocaine use (versus fentanyl, no cocaine use) and (2) fentanyl-methamphetamine use (versus fentanyl, no methamphetamine use).
Between 2015 and 2023, among fentanyl-related exposures, cocaine use increased from 1.3% to 10.0% (669.2% increase, p<0.001) and methamphetamine use increased from 1.5% to 10.8% (620.0% increase, p<0.001). Exposures in the Northeast were associated with higher odds of cocaine co-use, while exposures in the Midwest, South, and West were associated with higher odds of methamphetamine co-use. Compared to those with less severe effects, those with a major (life-threatening) effect had higher odds of cocaine co-use, but lower odds of methamphetamine co-use.
Similar to drug-related mortality trends, nonfatal fentanyl poisonings involving co-use of cocaine or methamphetamine increased in recent years and became increasingly widespread. Differences in experience of life-threatening adverse effects linked to different stimulants suggests varying risk according to which stimulant is involved.
在美国,涉及兴奋剂的芬太尼相关死亡人数有所增加,但对于涉及使用兴奋剂的非致命过量用药情况却知之甚少。本研究调查了涉及同时使用可卡因或甲基苯丙胺的非致命芬太尼相关暴露的全国趋势。
在这项横断面分析中,美国毒物控制中心的数据被用于估计2015年至2023年报告的涉及芬太尼和兴奋剂使用的暴露的年度趋势。病例包括年龄≥13岁、暴露涉及故意滥用或“误用”芬太尼且发生非致命不良反应的患者(n = 13173)。研究了共同暴露趋势,并使用多变量逻辑回归模型来估计地区和医疗结局严重程度与(1)芬太尼 - 可卡因联合使用(相对于芬太尼,未使用可卡因)以及(2)芬太尼 - 甲基苯丙胺联合使用(相对于芬太尼,未使用甲基苯丙胺)之间的关联。
在2015年至2023年期间,在与芬太尼相关的暴露中,可卡因使用从1.3%增加到10.0%(增加669.2%,p < 0.001),甲基苯丙胺使用从1.5%增加到10.8%(增加620.0%,p < 0.001)。东北部的暴露与更高的可卡因共同使用几率相关,而中西部、南部和西部的暴露与更高的甲基苯丙胺共同使用几率相关。与那些影响较轻的人相比,那些有严重(危及生命)影响的人有更高的可卡因共同使用几率,但甲基苯丙胺共同使用几率较低。
与药物相关的死亡率趋势相似,近年来涉及同时使用可卡因或甲基苯丙胺的非致命芬太尼中毒事件有所增加且日益普遍。与不同兴奋剂相关的危及生命的不良反应经历差异表明,根据所涉及的兴奋剂不同,风险也有所不同。